# Does Small Intestinal Bacterial Overgrowth Contribute to Functional Dyspepsia

> **NCT00956397** · NA · COMPLETED · sponsor: **Henry C. Lin, MD** · enrollment: 55 (actual)

## Conditions studied

- Functional Dyspepsia
- Small Intestinal Bacterial Overgrowth
- Chronic Abdominal Discomfort

## Interventions

- **DRUG:** Rifaximin
- **PROCEDURE:** Lactulose Breath Test
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00956397
- **Lead sponsor:** Henry C. Lin, MD
- **Sponsor class:** FED
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2012-03
- **Final completion:** —
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2012-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00956397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00956397, "Does Small Intestinal Bacterial Overgrowth Contribute to Functional Dyspepsia". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00956397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*